TITAN MEDICAL INC ORD - TMDIF STOCK NEWS

Titan Medical has entered into a second amending agreement with Conavi Medical, modifying the timeline for their proposed merger. Key dates have been extended, including the completion of the merger by September 30, 2024, and the commitment for concurrent financing by August 12, 2024. Additionally, Titan is seeking an extension from the Toronto Stock Exchange to hold its Annual General Meeting by September 30, 2024. This extension aims to reduce costs and provide more time to finalize the merger, which requires shareholder approval.

Titan Medical (TSX: TMD; OTC: TMDIF) has amended its amalgamation agreement with Conavi Medical, altering completion timelines for their merger. The new deadlines include:

- August 30, 2024, for the transaction completion.

- June 21, 2024, for financing and Conavi's financial statements.

- June 28, 2024, for mailing AGM information circulars.

- July 26, 2024, for holding AGMs.

Additionally, Conavi has advanced $150,000 to Titan to cover extension-related expenses. Titan has also received an extension from the Toronto Stock Exchange to hold its Annual General Meeting by July 31, 2024, to finalize the merger details.

Titan Medical (TMDIF) updated on its planned merger with Conavi Medical, as per the definitive Amalgamation Agreement dated March 17, 2024.

The merger involves delisting from TSX and listing on TSXV, with required submissions to TSXV currently underway.

A joint management information circular, needing TSXV approval, will be mailed to shareholders before Titan's annual meeting for their approval.

Conavi is also raising a minimum of $15M through subscription receipts convertible into shares before the merger completion.

Further details are available on SEDAR.

Titan Medical Inc. reported financial results for the first quarter of 2024, including recent activities such as entering into an amalgamation agreement with Conavi Medical Inc., settling a contractual dispute, and hosting a Q&A session with shareholders. The company expects to delist its common shares from the Toronto Stock Exchange and list them on the TSX Venture Exchange as part of the transaction. Financial highlights showed a decrease in cash and working capital, a recovery of R&D expenses, and a decrease in general and administrative expenses compared to the previous year.

Titan Medical Inc. provides an update on its planned merger with Conavi Medical Inc., focusing on the commercialization of Conavi's Novasight Hybrid™ System for minimally invasive coronary procedures.

Titan Medical Inc. settles dispute with a contract manufacturer by agreeing to pay US$2 million by June 24, 2024.

Titan Medical Inc. reported financial results for 2023, highlighting key activities such as new board appointments, licensing agreements, and a definitive amalgamation agreement with Conavi Medical Inc. The company improved its financial position with increased cash, working capital, and reduced financial obligations. Revenue significantly increased to $17.6 million, with a notable decrease in R&D and G&A expenses. Titan is focused on finalizing the amalgamation agreement with Conavi, subject to various approvals.

Titan Medical Inc. announces a webcast Q&A session regarding its merger agreement with Conavi Medical Inc. Management will provide prepared remarks followed by a Q&A session on March 27, 2024. Shareholders can submit questions in advance until March 25, 2024.

Titan Medical Inc. announces a merger with Conavi Medical Inc. to create a leader in hybrid intravascular imaging. The combined company will focus on commercializing Conavi's Novasight Hybrid™ System. The transaction involves a reverse takeover of Titan, delisting from TSX, and listing on TSXV. Conavi's technology has regulatory approvals and is set to enhance patient care globally.